-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine To Target Guanylyl Cyclase C For Oncology in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vaccine To Target Guanylyl Cyclase C For Oncology in Pancreatic Ductal Adenocarcinoma Drug Details: Ad5-hGCC-PADRE...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GLS-6100 in Hepatitis C
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GLS-6100 in Hepatitis C Drug Details: GLS-6100 is under development for the prevention of hepatitis C...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ruzasvir in Hepatitis C
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ruzasvir in Hepatitis C Drug Details: Ruzasvir is under development for the treatment of...
-
Company Profile
![]()
C&C Group plc – Company Profile
C&C Group Plc (C&C) manufactures, markets and distributes alcoholic beverages and soft drinks. The company's product portfolio comprises cider, beer, wine, carbonated drinks, and packaged water. C&C markets products under Bulmers, Matthew Clark, Tennent's, Blackthorn, and Magners brand names. The company owns and manufactures craft cider brands in the US. It manufactures Tipperary Water and Finches soft drinks through Gleeson Group. C&C operates manufacturing and packaging facilities in Co. Tipperary, Ireland; Glasgow, Scotland; and Vermont, the US. The company distributes...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GNS-214-C in Dyslipidemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GNS-214-C in Dyslipidemia Drug Details: GNS-214-C is under development for the treatment of dyslipidemia. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Orbcel-C in Autoimmune Hepatitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Orbcel-C in Autoimmune HepatitisDrug Details:Stem cell therapy is under development for the treatment of primary sclerosing...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TP-168 in Hepatitis C
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TP-168 in Hepatitis CDrug Details:TP-168 is under development for the treatment of hepatitis C virus infections....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Orbcel-C in Lupus Nephritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Orbcel-C in Lupus Nephritis Drug Details:Stem cell therapy is under development for the treatment of primary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BVAC-C in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BVAC-C in Cervical Cancer Drug Details:BVAC-C is under development for the treatment of human papilloma virus...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APX-3330 in Hepatitis C
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APX-3330 in Hepatitis C Drug Details: APX-3330 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – C-16G2 in Dental Caries
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.C-16G2 in Dental CariesDrug Details:C-16G2 is under development for the prevention of Streptococcus mutans sustained dental...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Orbcel-C in Rheumatoid Arthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Orbcel-C in Rheumatoid Arthritis Drug Details:Stem cell therapy is under development for the treatment of primary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EP-547 in Hepatitis C
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EP-547 in Hepatitis C Drug Details:EP-547 is under developmant for the treatment of cholestatic pruritus due to...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bemnifosbuvir Sulfate in Hepatitis C
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bemnifosbuvir Sulfate in Hepatitis C Drug Details: AT-527 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – C-106 in Pulmonary Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.C-106 in Pulmonary Hypertension Drug Details:C-106 is under development for the treatment of idiopathic pulmonary fibrosis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CIGB-230 in Hepatitis C
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CIGB-230 in Hepatitis C Drug Details: CIGB-230 is under investigation for the treatment of...
-
Product Insights
![]()
L12b-C Field, Netherlands
L12b-C upstream field is located in North Sea, Netherlands. The upstream field is owned by Delta Hydrocarbons BV (15%); EBN BV (50%); Neptune Energy Netherlands BV (30%); Wintershall Noordzee BV (5%). It is operated by Neptune Energy Netherlands BV. The project started its operations in 2001. L12b-C Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production,...
